ReviewOncoTargets and therapy2014
Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis.
Review in OncoTargets and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 176 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
176 citing papers in PubMed, 2 syntheses or guidelines pooled it, 309 citations in OpenAlex.
- The Chemoprotective Potentials of Alpha-lipoic Acid against Cisplatin-induced Ototoxicity: A Systematic Review.Current medicinal chemistry · 2024Pooled it
- A Systematic Review of the Potential Chemoprotective Effects of Resveratrol on Doxorubicin-Induced Cardiotoxicity: Focus on the Antioxidant, Antiapoptotic, and Anti-Inflammatory Activities.Oxidative medicine and cellular longevity · 2021Pooled it
- Psychobiotics Ameliorate Depression and Anxiety Status in Surgical Oncology Patients: Results from theNutrients · 2025Trial
- A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plusThe oncologist · 2019Trial
- Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up.Molecular oncology · 2017Trial
- Cancer treatment-related cognitive impairment.Neuro-oncology advances · 2026Review
- Neutrophil extracellular traps in the tumor microenvironment, metastasis, therapy, and beyond: advances, challenges, and perspectives.Journal of hematology & oncology · 2026Review
- Review
- An integrative approach to studying sphingolipid metabolism reveals p53 as a master regulator of the pathway.Journal of lipid research · 2026Article
- Molecular and Biochemical Evidence of Edaravone's Impact on Dasatinib-induced AGS Cell Senescence: A Promising Strategy for Gastric Cancer Therapy.Current medicinal chemistry · 2026Article
- Quantum Dots for Assessment of ROS Accumulation During Chemotherapy, Radiotherapy, and Chemoradiotherapy.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Redefining Chemotherapy-Related Headaches: From Pathobiology to Differential Diagnosis and Management.International journal of molecular sciences · 2025Review
- Sarcopenia and Cachexia in Older Patients with Cancer: Pathophysiology, Diagnosis, Impact on Outcomes, and Management Strategies.Drugs & aging · 2025Review
- Vascular endothelial generating factor pathway in ovarian cancer.Journal of ovarian research · 2025Review
- Enhancing Chemosensitivity With Quercetin: Mechanistic Insights Into MerTK and Associated Signaling Pathways.Cancer reports (Hoboken, N.J.) · 2025Review
- Plant-derived extracellular vesicles: composition, function and clinical potential.Journal of translational medicine · 2025Review
- Eye Movement Impairment in Women Undergoing Chemotherapy.Journal of eye movement research · 2025Article
- Review
- Vitamin C as a Cardioprotective Agent Against Doxorubicin-Induced Cardiotoxicity.Journal of the American Heart Association · 2025Review
- The Effect of Moringa Oleifera Ethanol Extract on Improving Cisplatin Induced Liver Cells Damages.Asian Pacific journal of cancer prevention : APJCP · 2025Article
116 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lack of therapy and the failure of existing therapy has been a challenge for clinicians in treating various cancers. Doxorubicin, 5-fluorouracil, cisplatin, and paclitaxel are the first-line therapy in various cancers; however, toxicity, resistance, and treatment failure limit their clinical use. Their status leads us to discover and investigate more targeted therapy with more efficacy. In this article, we dissect literature from the patient perspective, the tumor biology perspective, therapy-induced metastasis, and cell data generated in the laboratory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.